Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B - Containing lipoproteins in subjects with and without type 1 diabetes
Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B - Containing lipoproteins in subjects with and without type 1 diabetes
复制标题
DOI：
10.2337/diabetes.51.11.3300
复制
发表时间：
2002-11-01
期刊：
影响因子：
7.7
通讯作者：
Van Tol, A
中科院分区：
文献类型：
--
作者：
Colhoun, HM;Taskinen, MR;Van Tol, A
1型糖尿病患者的磷脂转移蛋白（PLTP）活性显著增加，HDL亚类分布发生改变。在195例1型糖尿病患者和194例30-55岁的男性和女性中，我们研究了PLTP活性与HDL的关系，并研究了PLTP活性是否有助于1型糖尿病中HDL的差异。使用外源性底物测定来测量PLTP活性。使用核磁共振光谱法测量平均高密度脂蛋白粒径和高密度脂蛋白亚类。免疫比浊法测定载脂蛋白AI（apoAI）和apoA Ⅱ。使用差示电免疫测定法测量存在于LpAI中的apoAI的量，并且从apoAI和LpAI数据推断LpAIAII中的apoAI的量。PLTP活性越高，大HDL含量越高（P < 0.001），小HDL含量越低（P < 0.01），apoAI和apoAII含量越高（均P < 0.001），LpAI和LpAIAII中apoAI含量越高（分别P = 0.02和P < 0.001）。这些协会是独立的其他脂质和酶的活动。调整PLTP活性后，糖尿病患者和非糖尿病患者之间apoA 1（从糖尿病患者的10.1 mg/dl高到4.6 mg/dl高）和大HDL（从2.4 mumol/l高到1.2 mumol/l高）的差异减半，HDL大小的差异减少（从0.31 nm高到0.26 nm高）。糖尿病患者PLTP活性与载脂蛋白B、总VLDL和LDL颗粒数以及IDL水平呈正相关。这些数据支持这样的观点：PLTP是人类HDL转化和重塑的主要因素，并且较高的PLTP活性对1型糖尿病中较高的apoAI水平和改变的HBL亚类分布做出了重要贡献。它们还支持PLTP在含apoB的脂蛋白代谢中的作用。
Patients with type 1 diabetes have greatly increased phospholipid transfer protein (PLTP) activity and have an altered HDL subclass distribution. In 195 patients with type 1 diabetes and in 194 men and women aged 30-55 years, we examined the relationship of PLTP activity to HDL and examined whether PLTP activity contributes to differences in HDL found in type 1 diabetes. PLTP activity was measured using an exogenous substrate assay. Average HDL particle size and HDL subclasses were measured using nuclear magnetic resonance spectroscopy. Apolipoprotein AI (apoAI) and apoAII were measured by immunoturbidimetry. The amount of apoAI present in LpAI was measured using a differential electroimmunoassay, and the amount of apoAI in LpAIAII was inferred from the apoAI and LpAI data. Higher PLTP activity was associated with more large HDL (P < 0.001) and less small HDL (P < 0.01), more apoAI and apoAII (both at P < 0.001), and more apoAI in both LpAI and LpAIAII (P = 0.02 and P < 0.001, respectively). These associations were independent of other lipids and enzyme activities. Adjusting for PLTP activity halved the difference between subjects with and without diabetes in apoA1 (from 10.1 mg/dl higher in subjects with diabetes to 4.6 mg/dl higher) and large HDL (2.4 mumol/l higher to 1.2 mumol/l higher) and reduced the difference in HDL size (from 0.31 run higher to 0.26 nm higher). PLTP activity was also positively associated with apoB, total VLDL and LDL particle number, and IDL level in subjects with diabetes. These data support the idea that PLTP is a major factor in HDL conversion and remodeling in humans and that higher PLTP activity makes an important contribution to the higher apoAI levels and altered HBL subclass distribution in type 1 diabetes. They also support a role for PLTP in the metabolism of apoB-containing lipoproteins.